.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
UBS
QuintilesIMS
Cerilliant
Medtronic
Merck
Teva
Boehringer Ingelheim
Mallinckrodt
Chinese Patent Office

Generated: July 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: High-affinity RNA ligands of basic fibroblast growth factor
Abstract:Methods are described for the identification and preparation of nucleic acid ligands and ligand solutions to basic fibroblast growth factor (bFGF). Included in the invention are nucleic acid ligands to bFGF which are inhibitors of bFGF and 2'-amino-modified RNA ligands to bFGF.
Inventor(s): Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Feb 10, 1994
Application Number:08/195,005
Claims:1. A method for identifying nucleic acid ligands to basic fibroblast growth factor (bFGF) comprising:

a) preparing a candidate mixture of nucleic acids,

b) contacting the candidate mixture with bFGF, wherein nucleic acids having sequences with an increased affinity to bFGF relative to the total candidate mixture may be partitioned from the remainder of the nucleic acids in the candidate mixture,

c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture, and

d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for sequences with increased affinity to bFGF, whereby nucleic acid ligands to bFGF may be identified.

2. The method of claim 1 further comprising e) repeating steps b) through d).

3. The method of claim 1 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.

4. The method of claim 3 wherein said candidate mixture of nucleic acids is comprised of RNA.

5. The method of claim 4 wherein said candidate mixture of nucleic acids is comprised of RNA wherein all pyrimidines are 2'-deoxy-2-NH.sub.2 pyrimidines.

6. A method for selecting a nucleic acid ligand which inhibits the binding of bFGF to its receptor, which comprises the additional step of screening nucleic acid ligands to bFGF identified by the method of claim 1 for their ability to inhibit the binding of bFGF to its receptor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Argus Health
Novartis
UBS
Daiichi Sankyo
Julphar
Teva
Colorcon
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot